Sanofi | Protocol ACT17746 (LIBERTY-UC SUCCEED) - Currently recruiting
Molecule: Dupilumab (Anti-Il4&13)
Study Title:
A Phase 2, multi-center, randomized, double-blind, placebo-controlled parallel-group study to evaluate the efficacy and safety of dupilumab therapy in patients with moderately to severely active ulcerative colitis with an eosinophilic phenotype.
Abivax | Protocol ABX464-105 - Currently Recruiting
Molecule: Obefazimod for Moderately to Severely Active Ulcerative Colitis
Study Title:
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
Merck | Protocol MK-7240-001 - Pending Approbation
Molecule: Tulisokibart For Moderately to Severely Active Ulcerative Colitis
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis
TAKEDA | Protocol TAK-279-UC-2001 - Pending Approbation
Molecule: Oral TAK-279 for Moderately to Severely Active Ulcerative Colitis
Study Title:
A Phase 2 Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis